Alnylam Pharmaceuticals (ALNY)

ALNY RNAi Therapeutics

BiotechSign Signal Grade

C
Signal Grade
52.8/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Publications
100
Dilution Risk
10
Clinical Activity
100
Short Interest
30

Pipeline Overview

Therapeutic Focus
RNAi Therapeuticssrc

Clinical Trial Activity

27
Clinical Trials
(ClinicalTrials.gov aggregate)
10 Phase 1, 8 Phase 2, 5 Phase 3
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-15. ClinicalTrials.gov

Dilution Risk

LOW DILUTION RISK
38.1 months
Cash Runway Estimate
10/100
Dilution Score
15Warrant Risk
15Convertible Risk
20Offering Ability

Dilution score: 10/100 (LOW), 38.1 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

5.80%
Float Shorted
6.5
Days to Cover
MODERATE
Squeeze Risk
+7.2%
SI Change
INCREASING
Trend
7,711,495
Shares Short

Short interest: 5.8% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Alnylam Pharmaceuticals.

Full ALNY Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.